BTSG Earnings

BTSG reported its earnings on 2025-10-28, showcasing a revenue of 3.00B against an estimate of 3.00B, resulting in a 0.6% surprise. The EPS was 0.3, surpassing the expected 0.33 by -9.09% . The stock experienced a 0.5% price change on the earnings day and a -2.31% change over the next five days, reflecting market reactions to the results.

Following BTSG's earnings announcement on 2025-10-28, the stock price moved by 0.50% on the day of the release. Over the subsequent five days, it saw a -2.31% change. Historically, BTSG's stock price tends to shift by an average of +0.19% in the 10 days leading up to earnings and +6.54% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BTSG’s annual revenue to reach 3.00B, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.31% and EPS estimates Revise Upward by 0.26% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BTSG's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.31%, while EPS estimates moved Revise Upward by 0.26% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BTSG's stock price typically moves by +0.19% in the 10 days before its earnings and +6.54% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 3.00B.

The earnings call summary indicates strong financial performance and optimistic guidance, with a focus on growth in key service lines like infusion and hospice. The company's strategic initiatives, such as AI investments and operational efficiencies, support the positive outlook. The Q&A highlights no significant headwinds and an expectation of sustained growth, with raised EBITDA guidance and a positive market reaction anticipated. Despite some management avoidance in specifics, the overall sentiment is positive, suggesting a likely stock price increase.